12 September 2022 in Cancer Immunology Research
Some patients with advanced clear-cell ovarian cancer (CCOC) respond to immunotherapy; however, little is known about the tumor microenvironment (TME) of this relatively rare disease. Here, we describe a comprehensive quantitative and topographical analysis of biopsies from 45 patients, 9 with Federation Internationale des Gynaecologistes et Obstetristes (FIGO) stage I/II (early CCOC) and 36 with FIGO stage III/IV (advanced CCOC). We investigated 14 immune cell phenotype markers, PD-1 and ligands, and collagen structure and texture. We interrogated a microarray data set from a second cohort of 29 patients and compared the TMEs of ARID1A-wildtype (ARID1Awt) versus ARID1A-mutant (ARID1Amut) disease. We found significant variations in immune cell frequency and phenotype, checkpoint expression, and collagen matrix between the malignant cell area (MCA), leading edge (LE), and stroma. The MCA had the largest population of CD138+ plasma cells, the LE had more CD20+ B cells and T cells, whereas the stroma had more mast cells and αSMA+ fibroblasts. PD-L2 was expressed predominantly on malignant cells and was the dominant PD-1 ligand. Compared with early CCOC, advanced-stage disease had significantly more fibroblasts and a more complex collagen matrix, with microarray analysis indicating “TGFβ remodeling of the extracellular matrix” as the most significantly enriched pathway. Data showed significant differences in immune cell populations, collagen matrix, and cytokine expression between ARID1Awt and ARID1Amut CCOC, which may reflect different paths of tumorigenesis and the relationship to endometriosis. Increased infiltration of CD8+ T cells within the MCA and CD4+ T cells at the LE and stroma significantly associated with decreased overall survival.
20 May 2018 in Journal of Clinical Oncology
5581Background: 10 year survival for ovarian cancer (OC) in the UK has improved from 18% (1971) to a predicted survival of 35% (2011). Historical data show pts with advanced CCOC have worse survival compared to other histological subtypes of epithelial OC. We sought to determine treatment type and outcome of CCOC pts at 2 UK gynaecological cancer centres. Methods: Medical records of pts with CCOC treated between 2002 and 2017 were reviewed. Data collected comprised pt and tumour characteristics, treatment and outcome. Results: 115 pts, median age 56 (29-86) years (y) with CCOC were identified: stage (S) I (62), II (16), III (23), IV (8) and unknown (6). 91 pts had pure CCOC and 24 had mixed histopathology: endometrioid (83%), serous (12%), other (5%). Endometriosis co-existed in 43 (37%) pts; 34 pure CCOC, 8 mixed endometrioid. BRCA mutations were present in 4/19 tested and MMR loss in 2/8 tested. 21/23 pts with a thromboembolic event and 9/10 pts with hypercalcaemia (2.72-3.63mmol/L) had advanced or recu...